α-硫辛酸改善胱氨酸尿症患者胱氨酸溶解度:2例儿科病例报告
胱氨酸尿症是一种常染色体隐性遗传病,导致儿童期反复出现胱氨酸肾结石。本文报告2例6岁和15岁儿科患者在常规枸橼酸钾治疗基础上加用α-硫辛酸(ALA),耐受良好,结石频率减少,1例现有结石消失,尿液胱氨酸容量增加、过饱和度降低,而胱氨酸排泄量和尿pH无变化。提示ALA可改善胱氨酸溶解度并预防结石形成。
要点
- ALA在2例儿科胱氨酸尿症患者中耐受良好,无不良反应。
- ALA治疗后结石频率减少,1例现有结石在2个月后消失。
- ALA改善尿液胱氨酸容量和过饱和度,不改变排泄量或尿pH。
核心结论
- ALA可改善胱氨酸尿症患者尿液中胱氨酸溶解度并预防结石形成,尤其适用于对饮食和枸橼酸盐治疗无反应者。
研究设计与样本
- 本文为2例儿科病例报告(6岁和15岁),在常规枸橼酸钾治疗基础上加用常规剂量ALA。
主要发现
- 2例患者均耐受ALA无不良反应,有症状和无症状肾结石频率减少,1例现有结石在ALA治疗2个月后消失。
- 患者1尿液胱氨酸容量从-223 mg/L升至-1 mg/L,患者2从+140 mg/L升至+272 mg/L。
- 患者1胱氨酸过饱和度从1.7降至0.88,患者2从0.64降至0.48。
- 胱氨酸排泄量和尿pH无变化。
临床怎么用
- 对于饮食和枸橼酸盐治疗无反应的儿科胱氨酸尿症患者,可考虑在常规治疗基础上加用ALA以改善胱氨酸溶解度并减少结石。
局限性
- 仅为2例病例报告,证据级别有限,需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cystinuria is an autosomal recessive disorder characterized by excessive urinary excretion of cystine, resulting in recurrent cystine kidney stones, often presenting in childhood. Current treatment options for cystinuria include dietary and/or fluid measures and potassium citrate to reduce cystine excretion and/or increase solubility. Tiopronin and D-penicillamine are used in refractory cases to bind cystine in urine, albeit with serious side effects. A recent study revealed efficacy of nutritional supplement α-lipoic acid (ALA) treatment in preventing kidney stones in a mouse model of cystinuria. Here, we report 2 pediatric patients (6 and 15 years old) with cystinuria who received regular doses of ALA in addition to conventional therapy with potassium citrate. Both patients tolerated ALA without any adverse effects and had reduced frequency of symptomatic and asymptomatic kidney stones with disappearance of existing kidney stones in 1 patient after 2 months of ALA therapy. ALA treatment markedly improved laboratory markers of cystine solubility in urine with increased cystine capacity (-223 to -1 mg/L in patient 1 and +140 to +272 mg/L in patient 2) and decreased cystine supersaturation (1.7 to 0.88 in patient 1 and 0.64 to 0.48 in patient 2) without any changes in cystine excretion or urine pH. Our findings suggest that ALA improves solubility of cystine in urine and prevents stone formation in patients with cystinuria who do not respond to diet and citrate therapy.
引用
- Cil O, Perwad F. α-Lipoic Acid (ALA) Improves Cystine Solubility in Cystinuria: Report of 2 Cases. Pediatrics. 2020. PMID: 32245805. doi:10.1542/peds.2019-2951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。